Skip to main content
Terug
IMTX logo

Immatics N.V.

Datakwaliteit: 100%
IMTX
NASDAQ Healthcare Biotechnology
€ 9,74
▲ € 0,54 (5,87%)
Marktkapitalisatie: 1,31B
Dagbereik
€ 9,34 € 10,00
52-Weeksbereik
€ 3,30 € 12,41
Volume
781.026
50D / 200D Gem.
€ 9,83 / € 8,38
Vorige Slotkoers
€ 9,20

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -6,9 0,2
P/B 2,7 3,0
ROE % -35,7 3,5
Net Margin % -391,0 3,8
Rev Growth 5Y % 8,6 9,7
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 21,00 +115.6%
Low: € 17,00 High: € 25,00
Forward WPA
-€ 1,54
Omzet Sch.
37,79M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 0,26
-€ 0,54 – -€ 0,01
 379,37M 1
FY2029 -€ 0,97
-€ 2,02 – -€ 0,04
 198,25M 1
FY2028 -€ 1,40
-€ 1,54 – -€ 1,23
 159,12M 3

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-05 -€ 0,48 -€ 0,34 +29,2%
2025-11-17 -€ 0,44 -€ 0,49 -11,5%
2025-08-13 -€ 0,38 -€ 0,66 -73,7%
2025-05-13 -€ 0,39 -€ 0,35 +10,3%
2025-03-27 -€ 0,33 € 0,48 +245,5%
2024-11-18 -€ 0,27 -€ 0,12 +55,6%
2024-08-13 -€ 0,35 -€ 0,18 +48,6%
2024-05-14 -€ 0,74 -€ 0,04 +94,6%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 8,55% annually over 5 years — modest growth
Earnings declined -1339,94% over the past year
Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -175,95M
PEG of 0,00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 77,58%

Groei

Revenue Growth (5Y)
8,55%
Revenue (1Y)-69,03%
Earnings (1Y)-1339,94%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-35,65%
ROIC-26,93%
Net Margin-390,95%
Op. Margin-371,65%

Veiligheid

Debt / Equity
0,03
Current Ratio11,72
Interest Coverage-197,41

Waardering

P/E Ratio
-6,92
Forward P/EN/A
P/B Ratio2,70
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -69,03% Revenue Growth (3Y) -5,46%
Earnings Growth (1Y) -1339,94% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,55% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 48,27M Net Income (TTM) -188,69M
ROE -35,65% ROA -33,57%
Gross Margin 100,00% Operating Margin -371,65%
Net Margin -390,95% Free Cash Flow (TTM) -175,95M
ROIC -26,93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 11,72
Interest Coverage -197,41
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,92 Forward P/E N/A
P/B Ratio 2,70 P/S Ratio 27,05
PEG Ratio 0,00 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 34,55 Fwd Earnings Yield N/A
FCF Yield -13,47%
Market Cap 1,31B Enterprise Value 975,64M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 48,27M 155,84M 54,00M 172,83M 34,76M
Net Income -188,69M 15,22M -96,99M 37,51M -95,06M
EPS (Diluted) -1,54 0,14 -1,20 0,54 -1,51
Gross Profit 48,27M 155,84M -64,67M 66,05M -52,81M
Operating Income -179,38M -38,62M -101,73M 29,95M -86,29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 562,10M 696,15M 509,97M 407,82M 174,65M
Total Liabilities 78,20M 121,30M 284,88M 194,66M 150,58M
Shareholders' Equity 483,89M 574,84M 225,08M 213,16M 24,06M
Total Debt 15,63M 16,20M 15,40M 14,56M 9,85M
Cash & Equivalents 345,77M 236,75M 218,47M 148,52M 132,99M
Current Assets 503,79M 629,56M 449,37M 377,15M 152,21M
Current Liabilities 42,99M 67,99M 156,55M 106,45M 95,15M